2002/05/01 by Tjarda van Heek, Anne E. Rader, G. Johan A. Offerhaus +4 · 11 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Adenocarcinoma #Cancer #Cancer Genomics and Diagnostics #Cholangiocarcinoma and Gallbladder Cancer Studies #Cytology #Internal medicine #Medical diagnosis #Medicine #Pancreas #Pancreatic and Hepatic Oncology Research #Pathology
paper · doi:10.1309/5rq0-jcqu-5xf2-51lq
openalex publication_date 2002/05/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/08/02
Between January 1997 and February 2000, 101 fine-needle pancreatic aspirates were obtained. After a cytologic diagnosis was made, possible molecular alterations were determined on the 94 aspirates with adequate tissue using a molecular panel (K-ras, p53, and DPC4 [MAD4] genes). The 94 aspirates were categorized as follows: diagnostic of adenocarcinoma, 48 (51%); atypical (suggestive of but not diagnostic of adenocarcinoma), 19 (20%); negative for adenocarcinoma, 25 (2 7%); diagnostic of a neoplasm other than adenocarcinoma, 2 (2%). Clinical follow-up revealed that 3 patients (12%) with negative cytologic diagnoses and 12 patients (63%) with atypical cytologic diagnoses had adenocarcinoma. Of 63 with a final diagnosis of adenocarcinoma, 42 (67%) had an alteration in at least 1 of the genes analyzed. In contrast, only 2 (6%) of 31 patients without adenocarcinoma had an alteration in 1 gene on the panel. Overall, the molecular analyses supported the diagnosis of adenocarcinoma in 6 (32%) of 19 aspirates originally diagnosed as atypical by cytology alone. A molecular panel that includes the K-ras, p53, and DPC4 (MAD4) genes correlates with and can supplement traditional cytologic diagnosis of pancreatic fine-needle aspirates.